bupropion has been researched along with Chemical Dependence in 76 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this article is to compare the efficacy of two prominent medications utilized in smoking cessation: bupropion and varenicline." | 8.86 | A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. ( Johnson, TS, 2010) |
| "These naturalistic data suggest that bupropion is well tolerated and may be an effective medication for the treatment of substance abusing adolescents with comorbid mood disorders and ADHD." | 7.73 | Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. ( Biederman, J; Daly, J; Prince, JB; Solhkhah, R; Van Patten, SL; Wilens, TE, 2005) |
| "There was described and discussed a case of methadone maintenance participant, former polydrug abuser, who has received a standard treatment with bupropion SR for smoking cessation." | 7.73 | [Bupropion in cigarettes smoking cessation by former polydrug user participating in methadone maintenance programme]. ( Habrat, B; Steinbarth-Chmielewska, K, 2005) |
| "Nicotine dependence is a significant addiction with many health consequences." | 6.47 | Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011) |
| "Seizures are a frequently reported adverse effect of bupropion in therapeutic oral doses; however, there are limited data about the consequences of nasal insufflation of bupropion." | 5.36 | Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. ( Kim, D; Steinhart, B, 2010) |
| "Previous trials examining the use of bupropion for smoking cessation therapy after myocardial infarction (MI) have been inconclusive." | 5.22 | Cessation treatment adherence and smoking abstinence in patients after acute myocardial infarction. ( Eisenberg, MJ; Filion, KB; Grandi, SM; Joseph, L; O'Loughlin, J; Paradis, G, 2016) |
| " Participants assigned to treatment as usual with concurrent smoking-cessation treatment received weekly individual smoking cessation counseling and extended-release bupropion (300 mg/d) during weeks 1-10." | 5.19 | A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. ( Bachrach, K; Brigham, GS; DeGravelles, E; Douaihy, A; Gardin, JG; Ghitza, U; Haynes, L; Hiott, B; Hodgkins, C; Kelly, TM; Kropp, F; Lewis, DF; Lindblad, R; Love, LD; McCann, M; Penn, P; Sharma, G; Sonne, SC; Theobald, J; VanVeldhuisen, P; Winhusen, TM, 2014) |
| "Bupropion's efficacy for smoking cessation in pregnant women is unknown." | 5.14 | The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. ( Brigham, EP; Chisolm, MS; Jones, HE; Strain, EC; Tuten, M, 2010) |
| "After initially successful smoking cessation the majority of patients relapse which stresses the addiction character of nicotine dependence." | 5.11 | [Bupropion SR for weaning from smoking in relapsed smokers: results of an open multicentre trial in Germany]. ( Bergmann, L; Herschel, M; Warncke, W, 2004) |
| " In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine)." | 4.93 | Pharmacotherapy for Substance Use Disorders. ( Klein, JW, 2016) |
| "Seizures of both immediate and delayed onset after ingestion of bupropion SR and bupropion XL formulations are well documented, but are less well characterized after insufflation." | 4.90 | An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System. ( Albertson, TE; Ford, JB; Lewis, JC; Owen, KP; Sutter, ME, 2014) |
| "The purpose of this article is to compare the efficacy of two prominent medications utilized in smoking cessation: bupropion and varenicline." | 4.86 | A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. ( Johnson, TS, 2010) |
| " Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity." | 4.82 | Anticraving medications for relapse prevention: a possible new class of psychoactive medications. ( O'Brien, CP, 2005) |
| " There are now effective treatments for nicotine addiction and, in the UK, specialist services for the treatment of smoking cessation are becoming available in all areas." | 4.81 | Smoking cessation: integrating recent advances into clinical practice. ( Coleman, T, 2001) |
| "These naturalistic data suggest that bupropion is well tolerated and may be an effective medication for the treatment of substance abusing adolescents with comorbid mood disorders and ADHD." | 3.73 | Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. ( Biederman, J; Daly, J; Prince, JB; Solhkhah, R; Van Patten, SL; Wilens, TE, 2005) |
| "There was described and discussed a case of methadone maintenance participant, former polydrug abuser, who has received a standard treatment with bupropion SR for smoking cessation." | 3.73 | [Bupropion in cigarettes smoking cessation by former polydrug user participating in methadone maintenance programme]. ( Habrat, B; Steinbarth-Chmielewska, K, 2005) |
| "Those with pre-treatment insomnia were more likely to be female (69." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "Bupropion has been evaluated as a potential treatment for MDD and substance dependence." | 2.77 | Bupropion in the treatment of problematic online game play in patients with major depressive disorder. ( Han, DH; Renshaw, PF, 2012) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity." | 2.75 | Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. ( Chakraborty, B; Manniche, PM; Meier, D; Schoedel, KA; Sellers, EM, 2010) |
| "Bupropion treatment was also associated with significantly reduced cigarette smoking, by almost five cigarettes per day (p=0." | 2.73 | Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. ( De La Garza, R; Heinzerling, KG; Ling, W; Newton, T; Rotheram-Fuller, E; Shoptaw, S; Steward, T; Swanson, AN; Wang, J, 2008) |
| "Nicotine dependence is a significant addiction with many health consequences." | 2.47 | Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011) |
| "Psychotherapy is still the mainstay of treatment; however, relapse rates are high." | 2.44 | Pharmacotherapy of methamphetamine addiction: an update. ( Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W, 2008) |
| "Pathological gambling is frequently comorbid with bipolar spectrum disorders, substance abuse/dependence, and attention-deficit/hyperactivity disorder (ADHD), and comorbidity may influence treatment response in pathological gambling." | 2.43 | Pharmacological treatments of pathological gambling. ( Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E, 2005) |
| "When treating adults with ADHD and substance abuse, clinicians should assess the relative severity of the substance abuse, the symptoms of ADHD, and any other comorbid disorders." | 2.42 | Impact of ADHD and its treatment on substance abuse in adults. ( Wilens, TE, 2004) |
| "We recorded evidence of polysubstance abuse (PSA) as patients who had had a documented diagnosis or laboratory evidence of abuse of at least two substances (drugs or ethanol)." | 1.37 | Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. ( Casey, ER; Mullins, ME; Scott, MG; Tang, S, 2011) |
| "Pretreatment with methylphenidate (0." | 1.37 | Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. ( Gilman, JP; Goldberg, SR; McCann, DJ; Panlilio, LV; Schindler, CW, 2011) |
| "Seizures are a frequently reported adverse effect of bupropion in therapeutic oral doses; however, there are limited data about the consequences of nasal insufflation of bupropion." | 1.36 | Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. ( Kim, D; Steinhart, B, 2010) |
| "Bupropion has been used in the treatment of patients with substance dependence based on its weak inhibition of dopamine and norepinephrine reuptake." | 1.36 | Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. ( Han, DH; Hwang, JW; Renshaw, PF, 2010) |
| "On arrival at hospital seizures arose." | 1.34 | Bupropion interference with immunoassays for amphetamines and LSD. ( Skripuletz, T; Vidal, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.26) | 18.7374 |
| 1990's | 10 (13.16) | 18.2507 |
| 2000's | 26 (34.21) | 29.6817 |
| 2010's | 33 (43.42) | 24.3611 |
| 2020's | 3 (3.95) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, FI | 1 |
| Noe, G | 1 |
| Martin, SO | 1 |
| Shah, K | 1 |
| Munjal, S | 1 |
| Swinford-Jackson, SE | 1 |
| O'Brien, CP | 2 |
| Kenny, PJ | 1 |
| Vanderschuren, LJMJ | 1 |
| Unterwald, EM | 1 |
| Pierce, RC | 1 |
| Castaldelli-Maia, JM | 1 |
| Loreto, AR | 1 |
| Guimarães-Pereira, BBS | 1 |
| Carvalho, CFC | 1 |
| Gil, F | 1 |
| Frallonardo, FP | 1 |
| Ismael, F | 1 |
| Andrade, AG | 1 |
| Ventriglio, A | 1 |
| Richter, KP | 1 |
| Bhugra, D | 1 |
| Klemperer, EM | 1 |
| Hughes, JR | 1 |
| Naud, S | 1 |
| Hankosky, ER | 1 |
| Bush, HM | 1 |
| Dwoskin, LP | 1 |
| Harris, DR | 1 |
| Henderson, DW | 1 |
| Zhang, GQ | 1 |
| Freeman, PR | 1 |
| Talbert, JC | 1 |
| Reeves, RR | 1 |
| Ladner, ME | 1 |
| Hilliard, WT | 1 |
| Barloon, L | 1 |
| Farley, P | 1 |
| Penn, JV | 1 |
| Koranek, A | 1 |
| Mori, T | 1 |
| Shibasaki, M | 1 |
| Ogawa, Y | 1 |
| Hokazono, M | 1 |
| Wang, TC | 1 |
| Rahmadi, M | 1 |
| Suzuki, T | 1 |
| Winhusen, TM | 1 |
| Brigham, GS | 1 |
| Kropp, F | 2 |
| Lindblad, R | 2 |
| Gardin, JG | 1 |
| Penn, P | 1 |
| Hodgkins, C | 1 |
| Kelly, TM | 1 |
| Douaihy, A | 1 |
| McCann, M | 1 |
| Love, LD | 1 |
| DeGravelles, E | 1 |
| Bachrach, K | 1 |
| Sonne, SC | 1 |
| Hiott, B | 1 |
| Haynes, L | 1 |
| Sharma, G | 2 |
| Lewis, DF | 1 |
| VanVeldhuisen, P | 1 |
| Theobald, J | 1 |
| Ghitza, U | 2 |
| Stall, N | 1 |
| Godwin, J | 1 |
| Juurlink, D | 1 |
| Lewis, JC | 1 |
| Sutter, ME | 1 |
| Albertson, TE | 1 |
| Owen, KP | 1 |
| Ford, JB | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 2 |
| Luther, JF | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 2 |
| Grandi, SM | 1 |
| Eisenberg, MJ | 1 |
| Joseph, L | 1 |
| O'Loughlin, J | 1 |
| Paradis, G | 1 |
| Filion, KB | 1 |
| Hu, LY | 1 |
| Lu, T | 1 |
| Chen, YT | 1 |
| Klein, JW | 1 |
| Elkashef, A | 1 |
| Vocci, F | 1 |
| Hanson, G | 1 |
| White, J | 1 |
| Wickes, W | 1 |
| Tiihonen, J | 1 |
| Dopheide, JA | 1 |
| Pliszka, SR | 1 |
| Edmunds-Ogbuokiri, J | 1 |
| Langguth, B | 1 |
| Hajak, G | 1 |
| Landgrebe, M | 1 |
| Unglaub, W | 1 |
| Chisolm, MS | 1 |
| Brigham, EP | 1 |
| Tuten, M | 1 |
| Strain, EC | 1 |
| Jones, HE | 1 |
| Herin, DV | 1 |
| Rush, CR | 1 |
| Grabowski, J | 1 |
| Kim, D | 1 |
| Steinhart, B | 1 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Schoedel, KA | 1 |
| Meier, D | 1 |
| Chakraborty, B | 1 |
| Manniche, PM | 1 |
| Sellers, EM | 1 |
| Han, DH | 2 |
| Hwang, JW | 1 |
| Renshaw, PF | 2 |
| Johnson, TS | 1 |
| Casey, ER | 1 |
| Scott, MG | 1 |
| Tang, S | 1 |
| Mullins, ME | 1 |
| Schindler, CW | 1 |
| Gilman, JP | 1 |
| Panlilio, LV | 1 |
| McCann, DJ | 2 |
| Goldberg, SR | 1 |
| Dunn, KE | 1 |
| Saulsgiver, KA | 1 |
| Sigmon, SC | 1 |
| Grief, SN | 1 |
| Reidy, L | 1 |
| Walls, HC | 1 |
| Steele, BW | 1 |
| Marti, J | 1 |
| Winhusen, T | 1 |
| Stitzer, M | 1 |
| Woody, G | 1 |
| Brigham, G | 1 |
| Adinoff, B | 1 |
| Green, C | 1 |
| Somoza, E | 1 |
| Li, SH | 2 |
| Phillips, D | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Gaynes, BN | 1 |
| Howland, RH | 1 |
| Zisook, S | 1 |
| Balasubramani, GK | 1 |
| Fava, M | 1 |
| Winchell, C | 1 |
| Rappaport, BA | 1 |
| Roca, R | 1 |
| Rosebraugh, CJ | 1 |
| Uhl, GR | 1 |
| Walther, D | 1 |
| Musci, R | 1 |
| Fisher, C | 1 |
| Anthony, JC | 1 |
| Storr, CL | 1 |
| Behm, FM | 1 |
| Eaton, WW | 1 |
| Ialongo, N | 1 |
| Rose, JE | 1 |
| Gifford, EV | 1 |
| Tavakoli, S | 1 |
| Wang, R | 1 |
| Hagedorn, HJ | 1 |
| Hamlett-Berry, KW | 1 |
| Noordsy, DL | 1 |
| Green, AI | 1 |
| Zernig, G | 1 |
| De Wit, H | 1 |
| Telser, S | 1 |
| Nienhusmeier, M | 1 |
| Wakonigg, G | 1 |
| Sturm, K | 1 |
| Berger, I | 1 |
| Kemmler, G | 1 |
| Saria, A | 1 |
| Bergmann, L | 1 |
| Warncke, W | 1 |
| Herschel, M | 1 |
| Wilens, TE | 2 |
| Khurshid, KA | 1 |
| Decker, DH | 1 |
| Berigan, T | 1 |
| Hollander, E | 1 |
| Sood, E | 1 |
| Pallanti, S | 1 |
| Baldini-Rossi, N | 1 |
| Baker, B | 1 |
| Solhkhah, R | 1 |
| Daly, J | 1 |
| Prince, JB | 1 |
| Van Patten, SL | 1 |
| Biederman, J | 1 |
| Doran, CM | 1 |
| Duszynski, KM | 1 |
| Beilby, JJ | 1 |
| Mattick, RP | 1 |
| Steinbarth-Chmielewska, K | 1 |
| Habrat, B | 1 |
| Jasmin, L | 1 |
| Narasaiah, M | 1 |
| Tien, D | 1 |
| Ling, W | 4 |
| Rawson, R | 1 |
| Shoptaw, S | 2 |
| Vidal, C | 1 |
| Skripuletz, T | 1 |
| Szobot, CM | 1 |
| Bukstein, O | 1 |
| Mercerolle, M | 1 |
| Denooz, R | 1 |
| Lachâtre, G | 1 |
| Charlier, C | 1 |
| Tyndale, R | 1 |
| Heinzerling, KG | 1 |
| Rotheram-Fuller, E | 1 |
| Steward, T | 1 |
| Wang, J | 1 |
| Swanson, AN | 1 |
| De La Garza, R | 2 |
| Newton, T | 1 |
| Griffith, JD | 1 |
| Carranza, J | 1 |
| Griffith, C | 1 |
| Miller, LL | 1 |
| Miller, L | 1 |
| Griffith, J | 1 |
| Margolin, A | 3 |
| Kosten, TR | 1 |
| Avants, SK | 3 |
| Wilkins, J | 1 |
| Beckson, M | 1 |
| Arndt, IO | 1 |
| Cornish, J | 1 |
| Ascher, JA | 1 |
| Gorelick, DA | 1 |
| Riggs, PD | 1 |
| Leon, SL | 1 |
| Mikulich, SK | 1 |
| Pottle, LC | 1 |
| Litten, RZ | 1 |
| Allen, JP | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Kinnell, HG | 1 |
| Coleman, T | 1 |
| Hollister, LE | 1 |
| Krajewski, K | 1 |
| Rustin, T | 1 |
| Gillespie, H | 1 |
| Kosten, T | 4 |
| Petrakis, I | 2 |
| Rothman, RB | 1 |
| Yutrzenka, GJ | 1 |
| Patrick, GA | 1 |
| Rosenberger, W | 1 |
| Lamb, RJ | 1 |
| Griffiths, RR | 1 |
| Rakatansky, H | 1 |
| Johanson, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes[NCT01077024] | Phase 3 | 538 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Treatment With Lorcaserin for Cocaine Use: The TLC Study[NCT03192995] | Phase 2 | 22 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to FDA alert regarding study drug safety) | ||
| Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype[NCT00894166] | Phase 3 | 606 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42. (NCT01077024)
Timeframe: Post-quit days 15-42
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 6.7 |
| Substance-treatment as Usual | 0.0 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: Week 10 assessment
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 25.5 |
| Substance-treatment as Usual | 2.2 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 3- month follow-up visits
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 19.1 |
| Substance-treatment as Usual | 3.0 |
point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 6 month visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 13.1 |
| Substance-treatment as Usual | 3.7 |
At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 3-month follow-up visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 74.3 |
| Substance-treatment as Usual | 68.8 |
At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 6 - months follow-up visit
| Intervention | percentage of participants (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 69.5 |
| Substance-treatment as Usual | 71.6 |
Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free. (NCT01077024)
Timeframe: Week 16
| Intervention | percentage of weeks (Number) |
|---|---|
| Smoking-cessation Treatment + Substance Treatment as Usual | 77.7 |
| Substance-treatment as Usual | 78.0 |
To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks
| Intervention | percent adherence (Mean) |
|---|---|
| Experimental | 51.6 |
| Control | 66.2 |
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks
| Intervention | mean percent of visit retention (Mean) | |
|---|---|---|
| Treatment Group | Control Group | |
| Mean Percent of Weekly Follow-up Visits by Treatment and Control Arms | 83 | 81 |
The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Proportion of self-reported weekly cocaine use by Time-Line-Follow-Up (TLFU) at baseline | Proportion of self-reported weekly cocaine use by TLFU at Week 12 | |
| Control | 6 | 6 |
| Experimental | 12 | 7 |
The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Urine positive samples with cocaine use at baseline | Urine positive samples with cocaine use at Week 12 | |
| Control | 0 | 1 |
| Treatment | 8 | 7 |
(NCT00894166)
Timeframe: point abstinence (7 days) at 6 months post-quit date
| Intervention | percentage of subjects (Number) |
|---|---|
| NRT Responder | 21.7 |
| Pre-Quit Randomization to Bupropion + NRT | 17.2 |
| Pre-Quit Randomization to Varenicline | 16.5 |
| Pre-Quit Randomization to NRT | 6.6 |
| Post-Quit Randomization to Bupropion + NRT | 10.0 |
| Post-Quit Randomized to Varenicline | 20.0 |
| Post-Quit Randomized to NRT | 13.3 |
A self report of no cigarettes smoked confirmed by expired air carbon monoxide of <=10ppm was the criterion for abstinence. (NCT00894166)
Timeframe: weeks 8-11 after quit date
| Intervention | percentage of subjects abstinent (Number) |
|---|---|
| NRT Responder | 59.2 |
| Pre-Quit Randomization to Bupropion + NRT | 28.3 |
| Pre-Quit Randomization to Varenicline | 23.3 |
| Pre-Quit Randomization to NRT | 16.0 |
| Post-Quit Randomization to Bupropion + NRT | 26.7 |
| Post-Quit Randomized to Varenicline | 37.1 |
| Post-Quit Randomized to NRT | 26.7 |
(NCT00894166)
Timeframe: continuous abstinence at 6 months post quit day
| Intervention | percentage of subjects (Number) |
|---|---|
| NRT Responder | 20.0 |
| Pre-Quit Randomization to Bupropion + NRT | 13.1 |
| Pre-Quit Randomization to Varenicline | 5.8 |
| Pre-Quit Randomization to NRT | 5.8 |
| Post-Quit Randomization to Bupropion + NRT | 10.0 |
| Post-Quit Randomized to Varenicline | 14.3 |
| Post-Quit Randomized to NRT | 10.0 |
18 reviews available for bupropion and Chemical Dependence
| Article | Year |
|---|---|
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
Topics: Animals; Biogenic Monoamines; Biological Transport; Carrier Proteins; Cocaine; Fluorescent Dyes; Hum | 2003 |
Study Characteristics Influence the Efficacy of Substance Abuse Treatments: A Meta-analysis of Medications for Smoking Cessation.
Topics: Benzazepines; Bupropion; Clinical Trials as Topic; Humans; Smoking Cessation; Smoking Cessation Agen | 2020 |
Bupropion diversion and misuse in the correctional facility.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Overdose; Humans; Mental Disorders; Prison | 2013 |
An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System.
Topics: Adolescent; Adult; Aged; Bupropion; California; Dose-Response Relationship, Drug; Female; Humans; In | 2014 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug T | 2016 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; | 2008 |
Attention-deficit-hyperactivity disorder: an update.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Antidepressive Agents, Second-Generati | 2009 |
Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies.
Topics: Animals; Behavior Therapy; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Clini | 2010 |
A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotin | 2010 |
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Huma | 2011 |
Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Clozapine; Humans; Schizo | 2003 |
Impact of ADHD and its treatment on substance abuse in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disord | 2004 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, I | 2005 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexon | 2005 |
Management of methamphetamine abuse and dependence.
Topics: Baclofen; Benzhydryl Compounds; Brain; Bupropion; Cognition Disorders; Cognitive Behavioral Therapy; | 2006 |
Attention deficit hyperactivity disorder and substance use disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimula | 2008 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl | 1999 |
Smoking cessation: integrating recent advances into clinical practice.
Topics: Administration, Cutaneous; Antidepressive Agents; Bupropion; Ganglionic Stimulants; Health Education | 2001 |
18 trials available for bupropion and Chemical Dependence
| Article | Year |
|---|---|
A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers.
Topics: Adult; Amphetamine-Related Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-R | 2014 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Cessation treatment adherence and smoking abstinence in patients after acute myocardial infarction.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Dose-Response Relationship, Drug; Double-Blind | 2016 |
The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder, Major; | 2010 |
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Atomoxetine Hydrochloride; Attention; Biogenic Mon | 2010 |
Bupropion in the treatment of problematic online game play in patients with major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Cohort | 2012 |
Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulants; Drug Therapy | 2012 |
A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans | 2012 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.
Topics: Adolescent; Benzazepines; Bupropion; Case-Control Studies; Cohort Studies; Dose-Response Relationshi | 2014 |
Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Bupropion; Caffeine; Cent | 2004 |
[Bupropion SR for weaning from smoking in relapsed smokers: results of an open multicentre trial in Germany].
Topics: Adult; Age of Onset; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Male; Nico | 2004 |
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulants; Femal | 2008 |
Bupropion: clinical assay for amphetamine-like abuse potential.
Topics: Adult; Animals; Antidepressive Agents; Appetite; Blood Pressure; Bupropion; Dextroamphetamine; Doubl | 1983 |
A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers.
Topics: Adult; Antidepressive Agents; Arousal; Blood Pressure; Body Temperature Regulation; Bupropion; Clini | 1983 |
A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients.
Topics: Adult; Bupropion; Cocaine; Double-Blind Method; Female; Humans; Male; Methadone; Placebos; Severity | 1995 |
An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Conduct Disorder; Dopamine Upt | 1998 |
Drugs for cocaine dependence: not easy.
Topics: Adult; Bupropion; Cocaine; Depressive Disorder; Female; Hospitalization; Humans; Male; Patient Dropo | 1992 |
40 other studies available for bupropion and Chemical Dependence
| Article | Year |
|---|---|
"Poor Person's Cocaine": Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients.
Topics: Bupropion; Cocaine; Diagnosis, Dual (Psychiatry); Humans; Insufflation; Substance-Related Disorders | 2023 |
The Persistent Challenge of Developing Addiction Pharmacotherapies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-R | 2021 |
Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study.
Topics: Adult; Brazil; Bupropion; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Fema | 2018 |
Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimu | 2018 |
Additional evidence of the abuse potential of bupropion.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Crime; Hallucinations; Hum | 2013 |
Comparison of the behavioral effects of bupropion and psychostimulants.
Topics: Animals; Behavior, Animal; Bupropion; Cocaine; Male; Methamphetamine; Mice; Motor Activity; Psychotr | 2013 |
Bupropion abuse and overdose.
Topics: Antidepressive Agents; Bupropion; Drug Overdose; Humans; Seizures; Substance-Related Disorders; Toba | 2014 |
Have we underestimated the possibility of bupropion sustained-release addiction?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2016 |
Pharmacists can help clinicians detect hidden substance abuse.
Topics: Adult; Bupropion; Delayed-Action Preparations; HIV Infections; Humans; Interprofessional Relations; | 2009 |
Abuse potential of bupropion nasal insufflation: a case report.
Topics: Administration, Intranasal; Bupropion; Female; Humans; Substance-Related Disorders; Young Adult | 2009 |
Seizures induced by recreational abuse of bupropion tablets via nasal insufflation.
Topics: Administration, Intranasal; Adult; Antidepressive Agents, Second-Generation; Bupropion; Diagnosis, D | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Brain; Bupropion; | 2010 |
Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay.
Topics: Amphetamine; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulants; | 2011 |
Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.
Topics: Animals; Bupropion; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Uptake Inhibi | 2011 |
Contingency management for behavior change: applications to promote brief smoking cessation among opioid-maintained patients.
Topics: Analgesics, Opioid; Behavior Therapy; Bupropion; Female; Humans; Male; Motivation; Opiate Substituti | 2011 |
Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine.
Topics: Amphetamines; Bupropion; Drug Interactions; Enzyme-Linked Immunosorbent Assay; False Positive Reacti | 2011 |
Assessing preferences for improved smoking cessation medications: a discrete choice experiment.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Logistic Mod | 2012 |
Wellbutrin®: misuse and abuse by incarcerated individuals.
Topics: Bupropion; Criminals; Humans; Prescription Drug Misuse; Prisoners; Risk Factors; Substance-Related D | 2012 |
Reanalysis of methamphetamine dependence treatment trial.
Topics: Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Male; Methamphetamine; Substance-Related Diso | 2012 |
Tobacco dependence diagnosis and treatment in Veterans Health Administration residential substance use disorder treatment programs.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Male; Mental Disor | 2013 |
Bupropion insufflation in a teenager.
Topics: Administration, Inhalation; Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Fe | 2004 |
Amphetamine-like stimulant cessation in an abusing patient treated with buproprion (Tardiev et al. 2004).
Topics: Bupropion; Dopamine Uptake Inhibitors; Humans; Methamphetamine; Substance-Related Disorders | 2004 |
Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Delayed-Action P | 2005 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Femal | 2006 |
[Bupropion in cigarettes smoking cessation by former polydrug user participating in methadone maintenance programme].
Topics: Bupropion; Dopamine Uptake Inhibitors; Electroencephalography; Heroin Dependence; Humans; Male; Meth | 2005 |
Noradrenaline is necessary for the hedonic properties of addictive drugs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Appetitive Behavior; Benzazepines; Biphenyl Compou | 2006 |
Bupropion interference with immunoassays for amphetamines and LSD.
Topics: Amphetamines; Antidepressive Agents, Second-Generation; Bupropion; Drug Interactions; False Positive | 2007 |
A fatal case of bupropion (Zyban) overdose.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cause of Death; Chromatography, High Pre | 2008 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Har | 2008 |
The rate hypothesis and agonist substitution approaches to cocaine abuse treatment.
Topics: Animals; Bupropion; Cocaine; Dopamine Uptake Inhibitors; Humans; Mazindol; Piperazines; Substance-Re | 1998 |
Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Bupropion; Depressive Disorde | 2000 |
Bupropion for smokers. Drug is almost identical in structure to diethylpropion, a controlled drug.
Topics: Amphetamines; Bupropion; Dopamine Uptake Inhibitors; Drug and Narcotic Control; Humans; Substance-Re | 2001 |
Bupropion reduces cocaine abuse in methadone-maintained patients.
Topics: Adult; Antidepressive Agents; Bupropion; Cocaine; Combined Modality Therapy; Drug Therapy, Combinati | 1991 |
An open pilot study of bupropion and psychotherapy for the treatment of cocaine abuse in methadone-maintained patients.
Topics: Antidepressive Agents; Bupropion; Cocaine; Humans; Methadone; Opioid-Related Disorders; Propiophenon | 1990 |
High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development.
Topics: Benztropine; Bupropion; Cocaine; Dopamine; Drug Evaluation, Preclinical; Humans; Mazindol; Nomifensi | 1990 |
Substitution of psychoactive drugs in pentobarbital-dependent rats.
Topics: Animals; Antidepressive Agents; Arousal; Body Weight; Brain; Bromazepam; Bupropion; Diazepam; Dose-R | 1990 |
Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine.
Topics: Animals; Antidepressive Agents; Bupropion; Conditioning, Operant; Discrimination, Psychological; Imi | 1990 |
Chocolate: pleasure or pain?
Topics: Antidepressive Agents; Bupropion; Cacao; Candy; Energy Intake; Habits; Humans; Plants, Edible; Propi | 1989 |
Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys.
Topics: Animals; Anti-Anxiety Agents; Appetite Depressants; Bupropion; Dextroamphetamine; Discrimination Lea | 1987 |